Premera provides commercial medical coverage to more than 2.6 million people worldwide.
“Mental health and behavioral health are of paramount importance in our society, and better access to appropriate providers and levels of care is absolutely essential. Premera’s expanded coverage for both OCD and depression will make a huge difference in patients’ lives,” said
To further support these expanded access trends, final and preliminary local coverage determinations, respectively, were recently released by CGS and NGS, two Medicare Administrative Contractors (MACs), reducing the number of prior medication failures. needed to qualify for TMS treatment for MDD of four to two. These MACs collectively represent 14.5 million lives covered, and once implemented, the changes will allow more than 60 million Medicare beneficiaries nationwide to qualify for Deep TMS depression coverage after one or two tries. failed drugs. Private payers including Anthem,
Additionally, NGS is now expanding its TMS coverage criteria to include Psychiatric Nurse Practitioners, making it the first MAC to join commercial payors who have already taken this step, including Magellan, Centene, HCSC, Premera,
BrainsWay’s patented H-Coil technology was first approved by the FDA for the treatment of depression in 2013 and OCD in 2018, and is designed to penetrate deeper and wider brain structures than traditional TMS coils .
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be prefaced by the words “intends”, “may”, “will”, “expects”, “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. These forward-looking statements and their implications are based on the current expectations of the Company’s management only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. . Further, historical results or the conclusions of scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted in the same way in light of additional research or other. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: insufficient financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in initiating and/or completing planned clinical studies and trials; failure to obtain regulatory approvals within the Company’s timelines, or at all; failure to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or failure to develop necessary improvements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in applicable laws and rules and regulations; adverse market perception and acceptance of Deep TMS technology; insufficiency or delays in reimbursement by third-party payers, including insurance companies and Medicare; inability to market Deep TMS, including internationally, by the Company or through third-party distributors; development of products by competitors; failure to develop and introduce new technologies, products and applications on a timely basis, which could cause the Company’s actual results or performance to differ materially from those contemplated in such forward-looking statements.
Any forward-looking statements in this press release speak only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by applicable securities laws. More detailed information on the risks and uncertainties affecting the Company can be found under the heading “Risk Factors” in the documents filed by the Company with the